{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-025765","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2022-11-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.247069+00:00","generated_at":"2026-06-21T12:23:47.079418+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"ALX Oncology appoints Scott Garland to Board of Directors effective Nov 28, 2022","bullets":["Appointed Scott Garland to Board of Directors effective November 28, 2022; Board size increased from 7 to 8.","Garland is CEO of PACT Pharma, former CEO of Portola Pharmaceuticals, with 30+ years in biopharma.","Automatic grant of initial stock options for 24,009 shares, vesting monthly over three years.","Garland also serves on boards of Calithera Biosciences and Day One Biopharmaceuticals."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-025765","json":"https://secwatch.observer/filing/0000950170-22-025765.json","markdown":"https://secwatch.observer/filing/0000950170-22-025765.md","text":"https://secwatch.observer/filing/0000950170-22-025765.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000095017022025765/0000950170-22-025765-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000095017022025765/alxo-20221128.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T12:23:47.079418+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c2f2c57bdc","claim":"Scott Garland was appointed as Director at ALX ONCOLOGY HOLDINGS INC.","evidence_excerpt":"Effective as of November 28, 2022, the Board of Directors of ALX Oncology Holdings Inc. (the “Company”) appointed Scott Garland to its Board of Directors and increased the size of its Board of Directors from seven to eight directors in connection with his appointment.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017022025765/0000950170-22-025765-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}